INDIANAPOLIS and LOUISVILLE, Ky., April 03, 2018 -- hc1.com®, the leader in healthcare relationship management, and Appriss Health, provider of the nation’s most comprehensive platform for substance use disorder (SUD), announced a partnership that will deliver to state government officials the data and insight they need to identify emerging opioid use disorder areas and proactively address the opioid epidemic to save lives.
hc1.com is the inventor of the hc1 Opioid Dashboard, a cloud-based information service that shows drug positivity rates down to the zip code level for prescription opioids and illicit drugs. The hc1 Opioid Dashboard analyzes more than 5 billion anonymous diagnostic test results and information from more than 3.8 million healthcare providers nationally to help local governments and health systems improve population health.
Appriss Health provides the prescription drug monitoring program (PDMP) platform to government agencies in 42 states and territories. Additionally, Appriss Health partners with National Association of Boards of Pharmacy (NABP) and 45 governing member states to provide the technology for PMP InterConnect, which enables real-time PDMP data sharing across state lines to help prescribers and pharmacists make better informed decisions and intervene earlier with patients. This data and more, including advanced analytics, scores, insights, resources, a MAT locator, alerts and messaging, are also made readily available to prescribers and pharmacists in clinical workflow through Appriss Health’s PMP Gateway managed service platform via electronic health record (EHR) and pharmacy management systems.
While officials have traditionally approached the prevention and identification of opioid use disorder using PDMPs and overdose data, where available, drug positivity results add an important third dimension to the fight. With this partnership, hc1.com and Appriss Health, with the appropriate state approvals, provide a one-of-a-kind dataset at the ready for state officials, enabling them to intervene locally before an opioid crisis happens.
“Addressing the growing opioid use disorder problem is a key focus of government officials today; a challenge, until now, has been access to additional leading indicators that allow officials to try to get ahead of the epidemic,” said Brad Bostic, chairman and CEO of hc1.com. “Our partnership with Appriss Health provides a powerful body of data that enables state governments to easily see emerging and current opioid hotspots so they can take action sooner.”
According to the Centers for Disease Control and Prevention (CDC), opioids were involved in more than 42,000 deaths in 2016.
“This Appriss Health and hc1 partnership answers the call to expanded sharing of critical and time sensitive opioid management data for those professionals and government agencies that need this information to engage patients in need of help and allocate state and federal resources where needed. More better, shared, timely and actionable data is critical to helping combat opioid misuse and abuse,” said Rob Cohen, president of Appriss Health. “Appriss Health and hc1 solutions are complementary, and can be used in multiple ways to help states contend with the opioid epidemic. By delivering the dataset of drug positivity rates and insights along with prescriptions written statewide, we can empower state governments to better understand where problems are emerging. In addition, this data can be used at the point of care to give providers easy access to real-time data when writing prescriptions.”
For more information on this partnership, contact [email protected] or https://apprisshealth.com/about/contact/.
About hc1.com
hc1.com®, the leader in healthcare relationship management, is passionate about unlocking the answers that solve critical healthcare challenges. hc1 has been adopted across more than 1,000 lab, post-acute care, and health system locations, including Cleveland Clinic, Catholic Health Initiatives, Nationwide Children’s Hospital and Sonic Healthcare. The company has received accolades from Gartner Research, was named "Best Healthcare CRM" by Frost & Sullivan and is the top rated solution in the KLAS Healthcare CRM report. Follow us on Twitter @hc1_HRM, LinkedIn, and Facebook.
About Appriss Health
Appriss Health provides the nation’s most comprehensive platform for early identification, prevention, and management of SUD. We provide state government agencies with the most advanced repository of controlled substance dispensing data and deliver real-time clinical decision support, critical insights, and interventions to physicians, pharmacists, and care team members. Our solutions help prescribers and dispensers assess and manage clinical risk by providing access to critical information at the point of care for hundreds of millions of patient encounters each year. Appriss Health provides the platform for PDMPs and access to non-PDMP data, analytics, tools, and resources from PDMPs, across state lines, and integrated within care team workflows. Sharing #knowledgeforgood, our solutions are improving patient safety and outcomes. For more information, please visit www.apprisshealth.com.
For more information contact:
For hc1.com:
Linda Muskin, 847-432-7300
[email protected]
For Appriss Health:
David Griffin, 502-815-3880
[email protected]


Shein Hong Kong IPO to Raise $1.7 Billion at $26.5 Billion Valuation
Jefferies Names AMEC Top China Semiconductor Equipment Pick
BofA Names ASML Top Semiconductor Equipment Pick on Growth, Valuation
Amazon Secures 200 MW Wind Power Deals in Sweden
Pinterest Stock Falls as CFO Julia Brau Donnelly Resigns
Trian Drops Wendy’s Take-Private Bid Plans, Shares Plunge 14%
GM Plans C$1.1 Billion Canada Investment Amid U.S. Tariff Pressure
Meta Agrees to $18 Billion Settlement, Tightens Teen Social Media Rules
BNP Paribas, KB Kookmin Eye $2 Billion Techcombank Stake
Nvidia Revenue Soars 106% as AI Demand Hits ‘Inflection Point’
Faraday Future Delivers First Robots in Middle East, Plans September Launches
Salesforce Shares Surge as AI Demand Powers Q2 Earnings Beat
Nvidia Pauses AI Cloud Financing Deals Amid Antitrust Concerns
Star Entertainment Shares Fall After A$307 Million FY2026 Loss
OpenAI AI Agent Swarm Behind Hugging Face Hack
Google Changes EU Spam Policy Amid Antitrust Scrutiny 



